CICC: Raise the target price of SinoPharm Group (01093.HK) to HK$8.60, maintain outperform rating.

Wisdom Finance APP has learned that CICC released a research report stating that it maintains its earnings forecast for China Resources Pharmaceutical Group (01093.HK) for 2025 and 2026. The current stock price corresponds to a 15.0 times/12.7 times price-to-earnings ratio for 2025/2026. The rating is maintained at outperform, considering the upward trend in valuation, the target price has been raised by 26.5% to HK$8.60, corresponding to a 16.9 times price-to-earnings ratio for 2025 and a 14.4 times price-to-earnings ratio for 2026, representing a 12.9% upside potential from the current stock price.